Novel antiplatelet and anticoagulant agents in the cardiac care unit

Cardiol Clin. 2013 Nov;31(4):533-44, viii. doi: 10.1016/j.ccl.2013.07.001. Epub 2013 Aug 9.

Abstract

This article reviews the pivotal studies of several novel antiplatelet (prasugrel and ticagrelor) and anticoagulant (dabigatran, rivaroxaban, and apixaban) agents. The clinical use of these drugs in cardiac intensive care is discussed, focusing on the management of acute coronary syndromes, ischemic stroke, atrial fibrillation, and venous thromboembolism.

Keywords: Acute coronary syndrome; Anticoagulants; Antiplatelet drugs; Atrial fibrillation; Percutaneous coronary intervention; Stroke; Venous thromboembolism.

Publication types

  • Review

MeSH terms

  • Acute Coronary Syndrome / drug therapy*
  • Acute Disease
  • Administration, Oral
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / prevention & control
  • Coronary Care Units
  • Critical Care
  • Drug Therapy, Combination
  • Electric Countershock / methods
  • Heart Valve Prosthesis
  • Hemorrhage / chemically induced
  • Hemorrhage / prevention & control
  • Humans
  • Intraoperative Care / methods
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Pulmonary Embolism / prevention & control
  • Time Factors
  • Venous Thromboembolism / prevention & control
  • Venous Thrombosis / prevention & control

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors